-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, CC6ORcXcgOD55CgJnxclK36CnC1/dD6Ixf0mPeiVynfYQIkqArQzCrEsXSwiscWL X+8gqDiGHS2FX2tpWpnQYw== 0000950133-02-000522.txt : 20020414 0000950133-02-000522.hdr.sgml : 20020414 ACCESSION NUMBER: 0000950133-02-000522 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20020214 GROUP MEMBERS: BB BIOTECH AG GROUP MEMBERS: BIOTECH FOCUS N.V. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: MEDIMMUNE INC /DE CENTRAL INDEX KEY: 0000873591 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 521555759 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-42057 FILM NUMBER: 02549387 BUSINESS ADDRESS: STREET 1: 35 W WATKINS MILL RD CITY: GAITHERSBURG STATE: MD ZIP: 20878 BUSINESS PHONE: 3014170770 MAIL ADDRESS: STREET 1: 35 W WATKINS MILL ROAD CITY: GAITHERSBURG STATE: MD ZIP: 20878 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BB BIOTECH AG CENTRAL INDEX KEY: 0000924223 STANDARD INDUSTRIAL CLASSIFICATION: UNKNOWN SIC - 0000 [0000] STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: VODERGASSE 3 STREET 2: SWITZERLAND CITY: SCHAFFHAUSEN STATE: V8 ZIP: CH-8300 BUSINESS PHONE: 411724 59 59 MAIL ADDRESS: STREET 1: VODERGASSE 3 STREET 2: SWITZERLAND CITY: SCHAFFHAUSEN STATE: V8 ZIP: CH-8300 SC 13G/A 1 w57602bsc13ga.txt AMENDMENT #3 TO SC 13G/A FOR MEDIMMUNE, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 3)* MEDIMMUNE, INC. --------------------------------------------------------------- (Name of Issuer) COMMON STOCK, PAR VALUE $.01 PER SHARE --------------------------------------------------------------- (Title of Class of Securities) 584699102 -------------------------- (CUSIP Number) ---------------------------------------------------------------------- (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [X] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed " for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Page 1 of 6 pages CUSIP No. 584699102 - --------------------------------------------------------------------------------------- 1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). BB BIOTECH AG - --------------------------------------------------------------------------------------- 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) [X] (b) [] - --------------------------------------------------------------------------------------- 3. SEC Use Only - --------------------------------------------------------------------------------------- 4. Citizenship or Place of Organization SWITZERLAND - --------------------------------------------------------------------------------------- Number of 5. Sole Voting Power Shares Beneficially -0- Owned by Each Reporting --------------------------------------------------------------- Person With: 6. Shared Voting Power 13,125,875 --------------------------------------------------------------- 7. Sole Dispositive Power -0- --------------------------------------------------------------- 8. Shared Dispositive Power 13,125,875 - --------------------------------------------------------------------------------------- 9. Aggregate Amount Beneficially Owned by Each Reporting Person 13,125,875 10. Check if the Aggregate Amount in Row (11) Excludes Certain shares 11. Percent of Class Represented by amount in Row (11) 5.3% - --------------------------------------------------------------------------------------- 12. Type of Reporting Person (See Instructions) HC, CO - ---------------------------------------------------------------------------------------
Page 2 of 6 pages CUSIP No. 584699102 - --------------------------------------------------------------------------------------- 1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). BIOTECH FOCUS N.V. - --------------------------------------------------------------------------------------- 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) [X] (b) [] - --------------------------------------------------------------------------------------- 3. SEC Use Only - --------------------------------------------------------------------------------------- 4. Citizenship or Place of Organization Netherlands Antilles - --------------------------------------------------------------------------------------- Number of 5. Sole Voting Power Shares Beneficially -0- Owned by Each Reporting --------------------------------------------------------------- Person With: 6. Shared Voting Power 13,125,875 --------------------------------------------------------------- 7. Sole Dispositive Power -0- --------------------------------------------------------------- 8. Shared Dispositive Power 13,125,875 - --------------------------------------------------------------------------------------- 9. Aggregate Amount Beneficially Owned by Each Reporting Person 13,125,875 10. Check if the Aggregate Amount in Row (11) Excludes Certain shares 11. Percent of Class Represented by amount in Row (11) 5.3% - --------------------------------------------------------------------------------------- 12. Type of Reporting Person (See Instructions) CO - ---------------------------------------------------------------------------------------
Page 3 of 6 pages CUSIP No. 584699102 - ------------------------------------------------------------------------------- ITEM 2. (a) Name of Person Filing BB Biotech AG ("BB Biotech") Biotech Focus N.V. ("Biotech Focus") (b) Address of Principal Business Office or, if none, Residence BB Biotech Biotech Focus Vordergasse 3 De Ruyterkade 62, Willemstad 8200 Schaffhausen Curacao CH/Switzerland Netherlands Antilles (c) Citizenship See Item No. 4 of cover pages. (d) Title of Class of Securities Common Stock, Par Value $.01 Per Share (e) CUSIP Number 584699102 ITEM 4. OWNERSHIP Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 13,125,875 (b) Percent of class: 5.3% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote -0- (ii) Shared power to vote or to direct the vote 13,125,875 (iii) Sole power to dispose or to direct the disposition of -0- (iv) Shared power to dispose or to direct the disposition of 13,125,875 ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY This statement is filed jointly by BB Biotech and Biotech Focus. Biotech Focus is a wholly-owned subsidiary of BB Biotech. Page 4 of 6 pages CUSIP No. 584699102 - ------------------------------------------------------------------------------- Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURES After reasonable inquiry and the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. BB BIOTECH AG Date: February 14, 2002 By: /s/ CATHY BRUGGER -------------------------- Name: Cathy Brugger Title: Signatory Authority Date: February 14, 2002 By: /s/ RUBINO DI GIROLAMO -------------------------- Name: Rubino Di Girolamo Title: Signatory Authority BIOTECH FOCUS N.V. Date: February 14, 2002 By: /s/ JAN BOOTSMA -------------------------- Name: Jan Bootsma Title: Signatory Authority Date: February 14, 2002 By: /s/ RUBINO DI GIROLAMO -------------------------- Name: Rubino Di Girolamo Title: Signatory Authority Page 5 of 6 pages CUSIP No. 584699102 - ------------------------------------------------------------------------------- EXHIBIT INDEX ------------- Exhibit 1: Agreement by and between BB Biotech and Biotech Focus with respect to the filing of this disclosure statement.* - --------------------- * Previously filed. Page 6 of 6 pages -----END PRIVACY-ENHANCED MESSAGE-----